Aclaris Therapeutics (ACRS) Other Operating Expenses (2016 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Other Operating Expenses of $1.8 million for Q1 2026, down 1.54% year-over-year from $1.8 million in Q1 2025, and down 4.33% quarter-over-quarter from $1.9 million in Q4 2025.
Aclaris Therapeutics (ACRS) Other Operating Expenses (2016 - 2026) Analysis & Trends
Aclaris Therapeutics' Other Operating Expenses history runs 11 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- In Q1 2026, Other Operating Expenses fell 1.54% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $9.6 million (down 90.63% YoY), while the FY2025 annual figure was $9.6 million, down 90.86% from the prior year.
- Other Operating Expenses for Q1 2026 stood at $1.8 million, down from $1.9 million in the prior quarter.
- The five-year high for Other Operating Expenses was $94.9 million in Q4 2024, with the low at -$13.2 million in Q4 2023.
- The 5-year median for Other Operating Expenses is $2.1 million (2024), against an average of $7.7 million.
- Peak annual rise in Other Operating Expenses reached 2475.56% in 2023, while the deepest fall reached 253.74% in 2023.
- Aclaris Therapeutics' Other Operating Expenses stood at $8.6 million in 2022, then plunged by 253.74% to -$13.2 million in 2023, then surged by 816.65% to $94.9 million in 2024, then plunged by 98.03% to $1.9 million in 2025, then fell by 4.33% to $1.8 million in 2026.
- Business Quant data shows ACRS's Other Operating Expenses at $1.8 million in Q1 2026, $1.9 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.75 Mn |
| Mar 31, 2026 | 1.79 Mn |
| Dec 31, 2025 | 1.87 Mn |
| Sep 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 3.35 Mn |
| Mar 31, 2025 | 1.82 Mn |
| Dec 31, 2024 | 94.91 Mn |
| Sep 30, 2024 | 3.21 Mn |
| Jun 30, 2024 | 2.11 Mn |
| Mar 31, 2024 | 4.64 Mn |
| Dec 31, 2023 | -13.24 Mn |
| Sep 30, 2023 | 9.89 Mn |
| Jun 30, 2023 | 92,000.00 |
| Mar 31, 2023 | 1.07 Mn |
| Dec 31, 2022 | 8.61 Mn |
| Sep 30, 2022 | 10.42 Mn |
| Jun 30, 2022 | -2.33 Mn |
| Mar 31, 2022 | -45,000.00 |
| Dec 31, 2021 | 3.35 Mn |
| Sep 30, 2021 | 2.00 Mn |